PHAT250117P15000
- 2.25
- 0.000.00%
Phathom Pharmaceuticals Newsroom
Insider Purchase: Director at $PHAT (PHAT) Buys 12,500 Shares
Shareholders in Phathom Pharmaceuticals (NASDAQ:PHAT) Have Lost 66%, as Stock Drops 12% This Past Week
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals Analyst Ratings
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Phathom Pharmaceuticals: Undervalued Opportunity With Strategic Moves for Extended Exclusivity
Express News | Phathom Pharmaceuticals Inc: Exclusivity Period Is Until May 3, 2032
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (Vonoprazan) Tablets
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Express News | Phathom Pharmaceuticals Inc : Jefferies Cuts Target Price to $17 From $20
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript Summary
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $27
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $28
Phathom Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $28
Phathom Pharmaceuticals Surpasses Expectations: Strong Q3 Performance and Bullish Outlook Drive Increased Revenue Estimates and Price Target
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates